Lactobacillus casei
ApprovedBiologic
Lactobacillus casei is one of 46 biologic programs targeting Leukemia. It is currently in Approved.
2
Indications
3
Total Trials
1
Active Trials
45
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
508 competitors in Leukemia
#DrugCompanyPhaseTrials
1Cytosar
TevaPhase 3
Fludara
SanofiPhase 3
Idamycin
PfizerPhase 3
Oncovin
Eli LillyPhase 3
Neoral
NovartisPhase 3
Novantrone
PfizerPhase 3
Cellcept
RochePhase 3
Neupogen
EEastern Cooperative Oncology Group
Phase 3
Rayos
RRoxane Laboratories
Phase 3
Busulfex
Akero TherapeuticsPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Lactobacillus casei. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Approved[1]
- Company
- GGeorgetown University